ESTRO 2024 - Abstract Book

S2165

Clinical - Upper GI

ESTRO 2024

All patients experienced grade (G) 2 adverse events or greater during the observation period: 2 patients (10%) had G2, 17 (81%) had G3, and 2 (10%) had G4. No G5 adverse events were observed. All patients completed the planned RT dose, although treatment had to be suspended in 7 patients (33%) for the following reasons: acute toxicities occurred in five patients (24%), radiation equipment issues occurred in one patient (5%), and one patient (5%) missed RT due to their observation of a national holiday. The mean length of suspension was 6 days (range: 1 – 32 days).